Asia Pacific Key To Speeding Up Drug Development, Says Quintiles VP Anand Tharmaratnam: An Interview With PharmAsia News (Part 2 of 2)
Helping facilitate the globalization of clinical trials is one of Asia's main contributions in advancing the pharmaceutical industry, says Quintiles Asia Pacific Head of Clinical Development Anand Tharmaratnam, who discussed innovation in the region with PharmAsia News' Australia Bureau. While the shift to outsourcing to Asia may have begun as a cost play, it is not necessarily cheaper on every front now; in fact, some things are more expensive in Asia, such as quality control and shifting blood samples. But outsourcing to Asia is quickly becoming a strategic imperative that builds upon the region's experience and expertise. In part one, Tharmartnam discusses the changing role for contract research organizations in the region, and in part two, he drills down to discuss differences among Asia Pacific countries in terms of drug development.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains







